/

Business

Psychedelic Business Spotlight: November 26

Psychedelic Business Spotlight: November 26

,
This week in psychedelic business news: Compass Pathways files another patent; Seelos Therapeutics raises big money; Cybin makes psychedelic therapy more accessible in NYC.

The Psychedelic Sector has Reached “Escape Velocity” | An interview with Cybin’s CEO (CYBN)

In this episode, James, The Psychedelic Investor, sits down with Doug Drysdale, CEO of Cybin (NYSE: CYBN) for the Psychedelic Spotlight podcast. In the interview, the two discuss Cybin’s psychedelic medicines portfolio, and where the psychedelic industry is going in the next few years. Can psychedelics heal mental health? The main topic was attempting to answer the question: can psilocybin heal mental health conditions like depression? Doug Drysdale spoke on the positive results we have seen in psilocybin for depression clinical trials, such as the Compass Pathways’ psilocybin (comp 360) for treatment-resistant depression phase 2b trial. Despite the apparent benefits of psilocybin, though, Doug Drysdale and Cybin argued that there were 3 core problems with using psilocybin in a therapy setting: the long duration of effect; the onset action period; and the variability of effect. Cybin has developed a new version of psilocybin, called CYB-003. CYB-003 has a shorter duration, reaches peak effect quicker, and has less variability in effect between individuals. Plus, it keeps all of the therapeutic benefits of psilocybin and its subjective effects. It is important to note that Cybin’s Cyb-003, their next-generation psilocybin, has only been tested in animals up until this point. They intend to start human clinical trials next year. James and Doug of Cybin also discussed the other Cybin projects, such as CYB-004, and their development strategy. They also discussed government policy, and whether the psychedelics sector has reaches escape velocity. In all, this psychedelic medicines conversation was fascinating and showed Cybin’s dedication towards improving mental health conditions, which are abysmal in the United States right now. Enjoy the episode! Follow us on social media! Instagram: @thepsychedelicinvestor Facebook: @thepsychedelicinvestor James’ Twitter: @Psy_Invest Maria’s Twitter (Producer & Editor): @Psy_Holy Want to collaborate? Send us an email at: thepsychedelicinvestor@gmail.com Music from: www.bensound.com Video editing: @themyaholy DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments. All of the information in this video is public information that James (The Psychedelic Investor) believes to be reliable but it is not guaranteed to be 100% accurate and as such should not be used as advice. Any opinions or thoughts from James (The Psychedelic Investor) are subject to change. #Cybin #Psilocybin #Psychedelics
PharmaTher Believes Ketamine Could Treat This Rare Neurological ConditionShutterstock.com

PharmaTher Believes Ketamine Could Treat This Rare Neurological Condition

,
The company is also exploring if ketamine can treat other neurological conditions, including Parkinson’s Disease, ALS, and CRPS.
How the COVID Pandemic Inspired Wakeful Travel's Psychedelic Integration Journals

How the COVID Pandemic Inspired Wakeful Travel’s Psychedelic Integration Journals

A travel journal company pivots from external trips to those unfolding in the mind, and the psychedelic community is embracing the one-of-a-kind integration workbook with open arms.

Does Jon Stewart Microdose Magic Mushrooms? | Plus Pirate Eye

Does Jon Stewart Microdosing Magic Mushrooms? Have you ever wanted to try microdosing magic mushrooms before, because Jon Stewart wants to! On a recent podcast episode of The Problem with Jon Stewart, the political comedian opened his show by saying “I’ve been microdosing the whole week!”, before clarifying that he just WANTS to try psychedelic microdosing. The satirist, sometimes known as America’s Conscience, is one of the most influential voices in media over the last 3 decades. His short and funny forrow into the psychedelics debate should help further propel the issue into the mainstream. Can microdosing help depression? Can Microdosing help mental health? Jon Stewart thinks so, though this claim needs to be verified by the medical establishment. Microdosing has become a popular trend for professionals in the last few decades, so it is not surprising that Jon Stewart knows about it. He is a man with his finger on America’s pulse. Link to podcast: https://open.spotify.com/episode/3OZV5DLbn33bNSUluLS7oX?si=qVoGF4cCS76x_MrM9h_slw Enjoy the episode! Follow us on social media! Instagram: @thepsychedelicinvestor Facebook: @thepsychedelicinvestor James’ Twitter: @Psy_Invest Maria’s Twitter (Producer & Editor): @Psy_Holy Want to collaborate? Send us an email at: thepsychedelicinvestor@gmail.com Music from: www.bensound.com Video editing: @themyaholy #jonstweart #thejonsteartproblem #psychedelics

A Deep Dive Into MindMed’s Microdosing Program: Project Flow | Plus a NEW LSD Microdosing Study

In today’s episode, we look at MindMed’s (Nasdaq: MNMD, NEO: MMED) Project Flow, which is their LSD microdosing division. At present, MindMed’s microdosing program is split into 2 projects: base testing of LSD microdoses in healthy individuals, and using LSD microdoses to treat adult ADHD. We will explore the progress made on both fronts, and where the program will expand to in the future, such as psilocybin (magic mushrooms) microdosing. Ultimately, MindMed wants to answer questions such as: Can microdosing psychedelics treat ADHD? Can microdosing LSD improve your concentration? Can microdosing decrease your anxiety? Does microdosing increase creativity? Does microdosing improve your mood? Recently MindMed announced they are ready to begin recruiting for a study testing the variations in effect when taking LSD microdoses in the morning, compared to at night. The study will also try to answer the last four above questions. We discuss this study extensively. Links: MindMed Project Flow: https://mindmed.co/psychedelic-inspired/#scroll_section-2 MindMed New study: https://psilocybinalpha.com/news/mindmed-launches-study-of-low-dose-lsd-effects-on-sleep-and-cognitive-measures Imperial College of London study: https://www.theguardian.com/science/2021/mar/02/microdosing-lsd-benefits-might-be-placebo-effect-study-finds Project Albert Quote: https://mindmed.co/news/press-release/mindmed-expands-psychedelic-microdosing-division-adds-groundbreaking-study-evaluating-lsd-microdosing-through-next-gen-digital-clinical-markers/ Kim Kuypers Study: https://www.nature.com/articles/s41598-021-01811-4 MindMed Investor’s Deck: https://mindmed.co/wp-content/uploads/2021/11/MindMed-Presentation-11.17-compressed.pdf LSD for ADHD: https://mindmed.co/news/press-release/mindmed-advances-phase-2-lsd-microdosing-trial-for-adult-adhd-appoints-principal-investigator/ https://mindmed.co/news/press-release/mindmeds-microdosing-division-further-expands-phase-2-clinical-trial-of-microdosing-lsdfor-adult-adhd/ Previous MindMed LSD study: https://mindmed.co/news/press-release/mindmed-announces-the-completion-of-phase-1-study-measuring-dosing-effects-of-lsd/ Enjoy the episode! Follow us on social media! Instagram: @thepsychedelicinvestor Facebook: @thepsychedelicinvestor James’ Twitter: @Psy_Invest Maria’s Twitter (Producer & Editor): @Psy_Holy Want to collaborate? Send us an email at: thepsychedelicinvestor@gmail.com Music from: www.bensound.com Video editing: @themyaholy DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments. All of the information in this video is public information that James (The Psychedelic Investor) believes to be reliable but it is not guaranteed to be 100% accurate and as such should not be used as advice. Any opinions or thoughts from James (The Psychedelic Investor) are subject to change. #Mindmed #MNMDstock #Microdosing

Psychedelic Business Spotlight: November 19

,
This week in psychedelic business news: Companies partner on new dosage method; MindMed investigates LSD microdosing; Health Canada allows a psilocybin production campus.

We NEED to Talk about the Compass Pathways Psilocybin-for-Depression Trial Results: A WIN for CMPS??

In today's episode, we discuss the results of the much awaited phase 2b clinical trial using psilocybin (comp360) to treat treatment-resistant-depression. This Compass Pathways (Nasdaq: CMPS) trial is so important for a couple of reasons: first, it is the largest ever psychedelics clinical trial, with 219 people completing the trial; and second because it is the furthest progressed psilocybin trial ever, being in phase 2b. So what did the results say? Can Magic Mushrooms treat depression? Can Psychedelics help Mental Health? Well, the results are mixed. About a quarter of the people who underwent Compass Pathways psychedelic therapy program, who received 25 mg of psilocybin (Comp 360), entered remission after 12 weeks. And almost a third of individuals in this group saw their depression symptoms decrease by 50% or more, as measured by the MADRS scale. This is more than double the success rate for the control group, showing strong significant effects of psilocybin therapy on depression. Therefore, it is clear that psychedelics like psilocybin CAN help mental health… at least somewhat However, many, myself included, were hoping for stronger results, such as the MDMA to treat PTSD phase 3 results that MAPS released earlier this year. This led to disappointment at the positive results, as they were not as game changing as we had hoped. In this episode, we describe Compass Pathways’ psilocybin for depression clinical trial, explain the results, and then try to put said results into context. We finish by looking towards the future, and discussing where Compass Pathways, and other psychedelic medicines companies like MindMed, Cybin and Small Pharma, should go from here. Enjoy the episode! Follow us on social media! Instagram: @thepsychedelicinvestor Facebook: @thepsychedelicinvestor James’ Twitter: @Psy_Invest Maria’s Twitter (Producer & Editor): @Psy_Holy Want to collaborate? Send us an email at: thepsychedelicinvestor@gmail.com Music from: www.bensound.com Video editing: @themyaholy Links: Compass Results: https://ir.compasspathways.com/static-files/0f9fbce8-2619-438b-a6ba-5bbe2ba08cf6 Montgomery-Asberg Depression Rating Scale (MADRS): https://en.wikipedia.org/wiki/Montgomerysberg_Depression_Rating_Scale MAPS MDMA-PTSD Study: https://www.nytimes.com/2021/05/03/health/mdma-approval.html Comp 360 Open Label Study: https://www.globenewswire.com/en/news-release/2021/10/20/2317456/0/en/Open-label-study-of-COMP360-psilocybin-therapy-for-depression-in-cancer-patients-demonstrates-feasibility-of-simultaneous-psilocybin-administration-in-small-groups.html MindMed Psilocybin SSRI Study: https://mindmed.co/news/press-release/mindmed-and-liechti-lab-provide-results-from-their-psilocybin-rd-collaboration/ DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments. All of the information in this video is public information that James (The Psychedelic Investor) believes to be reliable but it is not guaranteed to be 100% accurate and as such should not be used as advice. Any opinions or thoughts from James (The Psychedelic Investor) are subject to change. #CompassPathways #psilocybin #depression

Atai Life Sciences, Compass Pathways, MindMed & Cybin’s Q3 Financial Results Analysis – What’s Next?

Analyzing the Quarter 3 financial results of atai Life Sciences (Nasdaq: ATAI), Compass Pathways (Nasdaq: CMPS), MindMed (Nasdaq: MNMD) and Cybin (NYSE: CYBN). It’s earning season! In this episode we compare and contrast the financials of the four biggest companies in the psychedelic medicines space, atai, Compass Pathways, MindMed and CYBIN. All four released their Q3 financials in the past week. All four are the biggest psychedelic stocks We also look at some of the highlights of the past quarter for each company, and do some rough back of the napkin math to determine when they will need to raise more capital. Atai Life Sciences (atai stock) is the best financed company, and had a very eventful quarter. They started clinical trials studying r-ketamine, ibogaine, a schizophrenia drug and more. Compass Pathways (CMPS stock), the next best financed psychedelics company, released the results of their long awaited Comp 360 phase 2b clinical trial, testing treating Treatment-Resistant Depression with psilocybin. They also announced a new trial using comp 360 to treat PTSD, hired the famous Hamilton Morris, and acquired an IP portfolio of novel medicines. MindMed (MNMD Stock) had a quieter quarter, though it was still impressive. Despite having over a hundred million dollars in the bank, since they are spending so much on their million projects, they will likely have to raise capital through dilution within a year. Their work with LSD, 18-MC Psilocybin and more continues in the background, but this quarter was all about hiring talent. Cybin (CYBN stock) is in a bigger cash crunch, only having enough capital for roughly a year. This means they will almost certainly be raising capital soon. Despite this, they had a great quarter and announced that their lead drug candidate CYB-003, a modified version of psilocybin, shows great promise in animal models. Links: Atai: https://www.atai.life/2021/11/05/atai-life-sciences-reports-third-quarter-2021-financial-results-and-corporate-update/ Compass Pathways: https://compasspathways.com/financial-results-and-business-highlights-for-the-third-quarter-2021/ MindMed: https://www.prnewswire.com/news-releases/mindmed-announces-financial-results-for-the-third-quarter-2021-and-business-highlights-cash-balance-of-145-9-usd-185-4-cad-to-execute-on-diverse-clinical-pipeline-301423844.html Cybin: https://www.businesswire.com/news/home/20211115005552/en/Cybin-Inc.-Reports-its-Second-Quarter-Financial-Results-and-Recent-Business-Highlights Enjoy the episode! Follow us on social media! Instagram: @thepsychedelicinvestor Facebook: @thepsychedelicinvestor James’ Twitter: @Psy_Invest Maria’s Twitter (Producer & Editor): @Psy_Holy Want to collaborate? Send us an email at: thepsychedelicinvestor@gmail.com Music from: www.bensound.com Video editing: @themyaholy DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments. All of the information in this video is public information that James (The Psychedelic Investor) believes to be reliable but it is not guaranteed to be 100% accurate and as such should not be used as advice. Any opinions or thoughts from James (The Psychedelic Investor) are subject to change. #ataiLifeSciences #MindMed #Cybin

© 2023 Psychedelic Spotlight. | Owned and operated by PSYC Media Corporation, Inc. a US publicly traded company (OTCPink: PSYC) | All Rights Reserved.